Bevacizumab in the treatment of colorectal cancer.
Colorectal cancer is a common disease with therapy that has a proven effectiveness in the adjuvant and metastatic setting. Bevacizumab, a vascular endothelial growth factor inhibitor, is an antiangiogenesis monoclonal antibody that has benefit in response rate and overall survival when used in combination with existing metastatic colorectal cancer regimens. It is well tolerated with a few important side effects to be cognizant of, including hypertension, arterial thrombosis and bowel perforation. Existing treatment and research strategies are examining its use in the adjuvant setting or in combination with other angiogenesis inhibitors.
Cilley
Jeffrey C
JC
Northwestern University, 676 North Saint Clair, Suite 21-100, Chicago, IL 60611, USA,.
Barfi
Keren
K
Benson
Al B
AB
Mulcahy
Mary F
MF
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D015179:Colorectal Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D009389:Neovascularization, Pathologic / Q000378:metabolism / Q000517:prevention & control*; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology* / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab